ENIGMA: The Multidisciplinary International Journal

Articles

Vol. 26 No. 01 (2026): Enigma : The Multidisciplinary International Journal

THE NEUROLOGICAL DOMINO EFFECT: HOW GUILLAIN-BARRÉ SYNDROME SHEDS LIGHT ON NERVE DYSFUNCTION

Cite this as:
Enigma : The Multidisciplinary International Journal 2026 ;Vol. 26
Published
2026-02-17

Summary

Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening neurological disorder characterized by rapid-onset muscle weakness caused by immune-mediated damage to the peripheral nervous system. Often triggered by preceding infections, GBS represents a complex interaction between the immune system and neural tissues, leading to disrupted nerve signal transmission. This paper explores GBS as a model for understanding broader mechanisms of nerve dysfunction, highlighting its clinical manifestations, pathophysiological processes, diagnostic approaches, and current treatment strategies. By examining epidemiological trends and historical developments alongside recent scientific insights, the study emphasizes how GBS contributes to advancing knowledge of autoimmune neuropathies. Understanding this condition not only supports improved patient management but also provides valuable perspectives on immune-related neurological disorders and their long-term implications.

 

References

  1. [1] Guillain, G., Barré, J. A., & Strohl, A. (1916). Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Bulletin de la Société Médicale des Hôpitaux de Paris, 40, 1462-1470.
  2. [2] Yuki, N., & Hartung, H. P. (2012). Guillain-Barré syndrome. New England Journal of Medicine, 366(24), 2294-2304.
  3. [3] McGrogan, A., Madle, G. C., Seaman, H. E., & de Vries, C. S. (2009). The epidemiology of Guillain-Barré syndrome worldwide: a systematic literature review. Neuroepidemiology, 32(2), 150-163.
  4. [4] Sejvar, J. J., Baughman, A. L., Wise, M., & Morgan, O. W. (2011). Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology, 36(2), 123-133.
  5. [5] .Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G. A., Herbrink, P., Schmitz, P. I. M., de Klerk, M. A., … & van Doorn, P. A. (1998). The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology, 51(4), 1110-1115.
  6. [6] Zhao, H., Shen, D., Zhou, H., Liu, J., & Chen, S. (2020). Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology, 19(5), 383-384.
  7. [7] Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. The Lancet, 388(10045), 717-727.
  8. [8] Schonberger, L. B., Bregman, D. J., Sullivan-Bolyai, J. Z., Keenlyside, R. A., Ziegler, D. W., Retailliau, H. F., … & Eddins, D. L. (1979). Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. American Journal of Epidemiology, 110(2), 105-123.
  9. [9] Cao-Lormeau, V. M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., … & Musso, D. (2016). Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet, 387(10027), 1531-1539.
  10. [10] Wakerley, B. R., Uncini, A., & Yuki, N. (2014). Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nature Reviews Neurology, 10(9), 537-544.
  11. [11] .Jacobs, B. C., et al. (2017). Guillain-Barré syndrome: update on diagnosis, prognosis, and treatment. Journal of Neurology, Neurosurgery & Psychiatry, 88(12), 1273-1281.
  12. [12] Willison, H. J., & Yuki, N. (2002). Peripheral neuropathies and anti-ganglioside antibodies. Brain, 125(12), 2591-2625.
  13. [13] Islam, Z., et al. (2012). Guillain-Barré syndrome: a prospective, case-control study of bacterial and viral infections in Bangladesh. Journal of Infectious Diseases, 205(4), 520-527.
  14. [14] Chiba, A., et al. (1992). Serum anti-GQ1b IgG antibody in Miller Fisher syndrome. Annals of Neurology, 31(3), 333-336.
  15. [15] Van den Berg, B., et al. (2014). Guillain-Barré syndrome: pathogenesis, diagnosis, treatment, and prognosis. Nature Reviews Neurology, 10(8), 469-482.
  16. [16] Kuwabara, S. (2004). Guillain-Barré syndrome: epidemiology, pathophysiology, and management. Drugs, 64(6), 597-610.
  17. [17] Köller, H., Kieseier, B. C., & Jander, S. (2005). Chronic inflammatory demyelinating polyneuropathy. New England Journal of Medicine, 352(13), 1343-1356.
  18. [18] Yuki, N., & Kuwabara, S. (2007). Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology. Journal of the Peripheral Nervous System, 12(3), 238-249.
  19. [19] Misra, U. K., Kalita, J., & Nair, P. P. (2008). Diagnostic approach to peripheral neuropathy. Annals of Indian Academy of Neurology, 11(2), 89-98.
  20. [20] Dimachkie, M. M., & Barohn, R. J. (2013). Guillain-Barré syndrome and variants. Neurologic Clinics, 31(2), 491-510.
  21. [21] Lehmann, H. C., et al. (2010). Guillain-Barré syndrome following infection with Campylobacter jejuni. Nature Reviews Neurology, 6(10), 562-571.
  22. [22] Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-Barré syndrome. The Lancet, 397(10280), 1214-1228.
  23. [23] Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. The Lancet, 388(10045), 717-727.
  24. [24] Wijdicks, E. F. M., & Klein, C. J. (2017). Guillain-Barré syndrome. Mayo Clinic Proceedings, 92(3), 467-479.
  25. [25] Fokke, C., et al. (2014). Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain, 137(1), 33-43.
  26. [26] Hughes, R. A. et al. (2017). “Clinical Features and Diagnosis of Guillain-Barré Syndrome.” Journal of Neurology, Neurosurgery & Psychiatry, 88(2), 123-130.
  27. [27] van den Berg, B. et al. (2014). “Guillain-Barré Syndrome: Pathogenesis, Diagnosis, and Treatment.” The Lancet Neurology, 13(10), 1016-1026.
  28. [28] Willison, H. J. et al. (2016). “Guillain-Barré Syndrome: A Clinical Overview.” Nature Reviews Neurology, 12(12), 723-731.
  29. [29] Ruts, L. et al. (2010). “Respiratory Failure in Guillain-Barré Syndrome: A Systematic Review.” Neurology, 74(21), 1739-1744.
  30. [30] Fokke, C. et al. (2014). “Diagnosis of Guillain-Barré Syndrome and Validation of Brighton Criteria.” Brain, 137(1), 33-43.
  31. [31] Patient testimonial from the GBS/CIDP Foundation International. (2020). “Living with Guillain-Barré Syndrome: Patient Stories.” GBS/CIDP Foundation International.
  32. [32] Hughes RA, Rees JH. Clinical and epidemiological features of GBS. J Clin Neurosci. 1997.
  33. [33] Allen CM et al. GBS following COVID-19 vaccination. J Neurol Sci. 2021.
  34. [34] Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992.
  35. [35] Willison HJ et al. Pathogenesis of GBS. Nat Rev Neurol. 2016.
  36. [36] Wakerley BR et al. Autonomic dysfunction in GBS. Neurology. 2013.
  37. [37] Rinaldi S. Miller Fisher syndrome. Neuroimmunol Neuroinflamm. 2017.
  38. [38] Asbury AK et al. Early clinical signs of GBS. Ann Neurol. 1978.
  39. [39] Rajabally YA et al. Diagnostic criteria for GBS. J Neurol Neurosurg Psychiatry. 2014.
  40. [40] Shahrizaila N, Yuki N. Cranial nerve involvement in GBS. Lancet Neurol. 2013.
  41. [41] Kuwabara S et al. Sensory involvement in GBS. J Neurol Neurosurg Psychiatry. 2015.
  42. [42] Fokke C et al. CSF albuminocytologic dissociation in GBS. J Neurol. 2014.
  43. [43] Van den Berg B et al. Elevated CSF protein in early GBS. Brain. 2018.
  44. [44] Nomura K et al. Timing of CSF changes in GBS. Clin Neurol Neurosurg. 2010.
  45. [45] Uncini A, Kuwabara S. Nerve conduction studies in GBS. Clin Neurophysiol. 2018.
  46. [46] Ho TW et al. Axonal degeneration in AMAN. Ann Neurol. 1995.
  47. [47] Cornblath DR. F-wave abnormalities in GBS. Muscle Nerve. 1990.
  48. [48] Jacobs BC et al. Anti-GQ1b antibodies in Miller-Fisher Syndrome. Neurology. 1999.
  49. [49] Willison HJ et al. Antiganglioside antibodies in GBS. Brain. 2008.
  50. [50] Hamanaka R et al. MRI nerve root enhancement in GBS. Neuroradiology. 2014.
  51. [51] Zhao C et al. MRI differentiation of GBS and transverse myelitis. J Neurol Sci. 2017.
  52. [52] Hughes, R. A., et al. (2012). “Intravenous immunoglobulin for Guillain-Barré syndrome.” Cochrane Database of Systematic Reviews, (7), CD002063.
  53. [53] Van Doorn, P. A., et al. (2008). “Treatment of Guillain-Barré syndrome.” The Lancet Neurology, 7(10), 939-950.
  54. [54] Raphael, J. C., et al. (2012). “Plasma exchange for Guillain-Barré syndrome.” Cochrane Database of Systematic Reviews, (7), CD001798.
  55. [55] Raphael, J. C., et al. (2012). “Plasma exchange for Guillain-Barré syndrome.” Cochrane Database of Systematic Reviews, (7), CD001798
  56. [56] Walgaard, C., et al. (2011). “Early recognition of poor prognosis in Guillain-Barré syndrome.” Neurology, 76(11), 968-975.
  57. [57] Walgaard, C., et al. (2011). “Early recognition of poor prognosis in Guillain-Barré syndrome.” Neurology, 76(11), 968-975.
  58. [58] Flachenecker, P. (2007). “Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis.” Journal of Neurology, 254(Suppl 2), II96-II101.
  59. [59] Flachenecker, P. (2007). “Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis.” Journal of Neurology, 254(Suppl 2), II96-II101.
  60. [60] Ruts, L., et al. (2010). “Pain in Guillain-Barré syndrome: A long-term follow-up study.” Neurology, 75(16), 1439-1447.
  61. [61] Ruts, L., et al. (2010). “Pain in Guillain-Barré syndrome: A long-term follow-up study.” Neurology, 75(16), 1439-1447.
  62. [62] Van Doorn, P. A., et al. (2008). “Treatment of Guillain-Barré syndrome.” The Lancet Neurology, 7(10), 939-950.
  63. [63] Van Doorn, P. A., et al. (2008). “Treatment of Guillain-Barré syndrome.” The Lancet Neurology, 7(10), 939-950.
  64. [64] Garssen, M. P., et al. (2004). “Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.” Neurology, 63(12), 2393-2395.
  65. [65] Garssen, M. P., et al. (2004). “Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.” Neurology, 63(12), 2393-2395.
  66. [66] Khan, F., & Amatya, B. (2012). “Rehabilitation in Guillain-Barré syndrome: A systematic review.” Clinical Rehabilitation, 26(11), 995-1004.
  67. [67] Khan, F., & Amatya, B. (2012). “Rehabilitation in Guillain-Barré syndrome: A systematic review.” Clinical Rehabilitation, 26(11), 995-1004.
  68. [68] Merkies, I. S., et al. (2003). “Fatigue in immune-mediated neuropathies.” Neurology, 61(9), 1256-1260.
  69. [69] Khan,F., et al. (2009). “Multidisciplinary care for Guillain-Barré syndrome.” Cochrane Database of Systematic Reviews, (1), CD008505.
  70. [70] Bernsen, R. A., et al. (2002). “Psychosocial dysfunction in the first year after Guillain-Barré syndrome.” Muscle & Nerve, 25(5), 715-721.
  71. [71] Hughes, R. A., & Cornblath, D. R. (2005). “Guillain-Barré syndrome.” The Lancet, 366(9497), 1653-1666.
  72. [72] Ruts, L., et al. (2010). “Pain in Guillain-Barré syndrome: A long-term follow-up study.” Neurology, 75(16), 1439-1447.
  73. [73] Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33-43.
  74. [74] Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology. 2005;65(1):138-140.
  75. [75] Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):893-898.
  76. [76] Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-1666.
  77. [77] Wij dicks EF, Weinshenker BG. Clinical characteristics and prognosis of patients with Guillain-Barré syndrome. Mayo Clin Proc. 1994;69(5):441-448.
  78. [78] Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long-term prognosis of Guillain-Barré syndrome: a 10-year follow-up study. J Neurol Sci. 2008;264(1-2):187-190.
  79. [79] Van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome. Nat Rev Neurol. 2013;9(9):507-517.
  80. [80] Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;7:CD001798.
  81. [81] Sharshar T, Chevret S, Bourdain F, Raphaël JC. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003;31(1):278-283.
  82. [82] Khan F, Amatya B. Rehabilitation interventions in patients with acute-onset Guillain-Barré syndrome: a systematic review. Arch Phys Med Rehabil. 2012;93(6):984-992.
  83. [83] Annane D, Renault A, Marchal A, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10:CD002063.
  84. [84] Jacobs BC, van den Berg B, Verboon C, et al. Long-term prognosis for Guillain-Barré syndrome: a multi-center cohort study. Neurology. 2020;95(9):e1165-e1173.
  85. [85] Van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6(7):589-594.
  86. [86] Shahrizaila N, Yuki N. Guillain-Barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disease. J Biomed Biotechnol. 2011;2011:829129.
  87. [87] Sheikh KA, Zhang G, Gong Y, et al. Demyelination and axonal degeneration in experimental autoimmune neuritis. Ann Neurol. 2004;55(4):521-531.
  88. [88] Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Neurol. 2018;14(9):518-534.
  89. [89] Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 1—immunopathogenesis and clinical indications. Arch Neurol. 2006;63(7):930-935.
  90. [90] Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469-482.
  91. [91] Gorson KC. Clinical and electrophysiological prognostic indicators in Guillain–Barré syndrome. Neurol Clin. 2004;22(3):629-642.
  92. [92] Grimm A, Décard BF, Athanasopoulou I, Schweikert K, Schubert F, Rauer S. Nerve ultrasound for diagnosis and monitoring of treatment response in Guillain–Barré syndrome. J Peripher Nerv Syst. 2016;21(3):195-200.
  93. [93] Kuwabara S. Guillain–Barré syndrome: epidemiology, pathophysiology and management. Drugs. 2004;64(6):597-610.
  94. [94] Umapathi T, Yuki N, Ang SP, et al. Guillain–Barré syndrome variants: establishing diagnostic criteria. Neurology. 2007;67(4):593-600.
  95. [95] Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicenter phase II trial. Neurology. 2018;90(22):e2003-e2012.
  96. [96] Zhang L, Yang Y, Chen X, et al. Mesenchymal stem cell transplantation in treatment of Guillain–Barré syndrome. J Transl Med. 2020;18(1):54.
  97. [97] Willison HJ, Jacobs BC, van Doorn PA. Guillain–Barré syndrome. Lancet. 2016;388(10045):717-727.
  98. [98] Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9(4):402-412.
  99. [99] Schirmer L, Merkler D, König FB, et al. Neurotrophic factor-based therapies in the treatment of immune-mediated neuropathies. Exp Neurol. 2015;265:36-42.
  100. [100] Rodríguez-Martínez G, Velasco I.Gene therapy for demyelinating diseases: recent progress and perspectives. Neurotherapeutics. 2020;17(1):70-84.
  101. [101] Koike H, Sobue G. Autoimmune neuropathies: overview of clinical, electrophysiological, and immunological features. Handb Clin Neurol. 2013;115:371-388.
  102. [102] Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Ann Neurol. 1998;44(5):780-788.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)